Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions
- PMID: 30141373
- DOI: 10.1089/thy.2017.0572
Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions
Abstract
Background: The American Joint Committee on Cancer Cancer Staging System for differentiated thyroid cancer has been recently revised. The purpose of this study was to compare survival prognostication between the seventh and eighth editions.
Materials and methods: We retrospectively reviewed 2579 differentiated thyroid cancer patients who underwent surgery at MD Anderson Cancer Center between 2000 and 2015. Disease-specific survival (DSS) and overall survival were estimated using the Kaplan-Meier method and compared using log rank test. The effect of potential predictor was estimated using Cox proportional hazards model. Power of survival prediction was estimated using Harrell's C concordance index (C-index), and predictive capacities for DSS were estimated using proportion of variance explained (PVE).
Results: Revision of tumor-node-metastasis (TNM) categories, age cutoff, and stage reassignment in the 8th edition caused reclassification of overall stage compared with the seventh edition. The proportion of patients in stage I and II increased from 62% to 83% and 5% to 12%, respectively, while the proportion of patients in stage III and IV decreased from 20% to 2% and 14% to 3%, respectively. Ten-year DSS for stages I-IV based on the seventh edition were 100%, 97.5%, 98.3%, and 82.6%, respectively, while 10-year DSS for the corresponding stage in the eighth edition were 99.8%, 88.3%, 72.4%, and 71.9%, respectively. In multivariate analysis for both seventh edition (C-index 0.94, PVE 4.6%) and eighth edition (C-index 0.94, PVE 4.8%), the factors predictive of worse outcome for DSS were older age, advanced tumor size category, and distant metastasis while cervical lymph node metastases did not predict worse survival. For the eighth edition, patients <55 years of age with stage II disease had significantly worse DSS (p < 0.001) than patients ≥55 years with stage II disease but appeared to be similar to patients ≥55 years with stage III (p = 0.742) and IV disease (p = 0.566). Patients ≥55 years old with T3a and T3b disease had 10-year DSS of 67% and 92%, respectively (p = 0.390).
Conclusion: The AJCC eighth edition is similar to the seventh edition in disease-specific survival prediction. Potential modifications that may improve disease-specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients <55 years of age with distant metastases.
Keywords: AJCC staging; age; differentiated thyroid cancer; prognosis; recurrence; survival; thyroid neoplasm.
Similar articles
-
Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.Thyroid. 2018 Aug;28(8):976-981. doi: 10.1089/thy.2018.0066. Epub 2018 Jul 30. Thyroid. 2018. PMID: 29848239
-
Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts.Thyroid. 2017 Nov;27(11):1408-1416. doi: 10.1089/thy.2017.0306. Epub 2017 Oct 5. Thyroid. 2017. PMID: 28891405 Free PMC article.
-
Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.Oral Oncol. 2018 Dec;87:97-103. doi: 10.1016/j.oraloncology.2018.10.029. Epub 2018 Oct 26. Oral Oncol. 2018. PMID: 30527251
-
Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA Cancer J Clin. 2018 Jan;68(1):55-63. doi: 10.3322/caac.21439. Epub 2017 Nov 1. CA Cancer J Clin. 2018. PMID: 29092098 Free PMC article. Review.
-
Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis.Oncologist. 2021 Feb;26(2):e251-e260. doi: 10.1634/theoncologist.2020-0306. Epub 2020 Sep 16. Oncologist. 2021. PMID: 32864832 Free PMC article.
Cited by
-
Rare sites of metastases in patients with differentiated thyroid carcinoma and added value of SPECT/CT over planar whole body radioactive iodine scan.Eur J Hybrid Imaging. 2022 Nov 28;6(1):34. doi: 10.1186/s41824-022-00155-0. Eur J Hybrid Imaging. 2022. PMID: 36437402 Free PMC article.
-
Vitamin D Status and VDR Polymorphisms as Prognostic Factors in Differentiated Thyroid Carcinoma.In Vivo. 2022 Sep-Oct;36(5):2434-2441. doi: 10.21873/invivo.12977. In Vivo. 2022. PMID: 36099120 Free PMC article.
-
Age and Post-Lobectomy Recurrence after Endoscopic or Robotic Thyroid Surgery: A Retrospective Cohort Study of 2348 Papillary Thyroid Carcinoma Patients.Cancers (Basel). 2023 Nov 21;15(23):5506. doi: 10.3390/cancers15235506. Cancers (Basel). 2023. PMID: 38067209 Free PMC article.
-
Newly proposed survival staging system for poorly differentiated thyroid cancer: a SEER-based study.J Endocrinol Invest. 2023 May;46(5):947-955. doi: 10.1007/s40618-022-01958-5. Epub 2022 Dec 9. J Endocrinol Invest. 2023. PMID: 36484934
-
Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.Front Endocrinol (Lausanne). 2022 Mar 2;13:842424. doi: 10.3389/fendo.2022.842424. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35311230 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical